Belgian FAMHP authorizes C3BS Phase III Congestive Heart failure ... News-Medical.net The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian ... |
